Partner Christopher Swift was quoted in a Washington Times article, “’Looking forward to it’: Trump says he can succeed where others failed with Putin summit,” about the prospects for a successful U.S.-Russian summit later this month in Finland.
Swift said the Trump administration is making the same mistakes with respect to accommodating Russian President Vladimir Putin that previous administrations have made. He said every administration thinks it can do a better job with the Russians than its predecessor did, but that such early optimism always ends in disappointment.
“That’s because of Putin. It’s not because of us,” he said. “Republicans and Democrats have had the same problem for the last 20 years that Putin has been in power. It’s who the other side is.”
Swift said the Trump administration is making the same mistakes with respect to accommodating Russian President Vladimir Putin that previous administrations have made. He said every administration thinks it can do a better job with the Russians than its predecessor did, but that such early optimism always ends in disappointment.
“That’s because of Putin. It’s not because of us,” he said. “Republicans and Democrats have had the same problem for the last 20 years that Putin has been in power. It’s who the other side is.”
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."